Exact Sciences EXAS underwent analysis by 19 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 14 | 5 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 0 | 0 | 0 | 0 |
| 3M Ago | 10 | 4 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $73.63, a high estimate of $95.00, and a low estimate of $60.00. This current average has decreased by 5.94% from the previous average price target of $78.28.
Deciphering Analyst Ratings: An In-Depth Analysis
A clear picture of Exact Sciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Luke Sergott | Barclays | Announces | Overweight | $70.00 | - |
| Bruce Jackson | Benchmark | Maintains | Buy | $65.00 | $65.00 |
| Derik De Bruin | B of A Securities | Lowers | Buy | $72.00 | $75.00 |
| Dan Brennan | TD Cowen | Raises | Buy | $86.00 | $82.00 |
| Mark Massaro | BTIG | Raises | Buy | $75.00 | $65.00 |
| David Westenberg | Piper Sandler | Lowers | Overweight | $75.00 | $85.00 |
| Patrick Donnelly | Citigroup | Lowers | Buy | $75.00 | $80.00 |
| Brandon Couillard | Jefferies | Raises | Buy | $85.00 | $84.00 |
| Mark Massaro | BTIG | Lowers | Buy | $65.00 | $82.00 |
| Daniel Arias | Stifel | Lowers | Buy | $67.00 | $82.00 |
| Kyle Mikson | Canaccord Genuity | Lowers | Buy | $75.00 | $95.00 |
| Dan Brennan | TD Cowen | Lowers | Buy | $82.00 | $90.00 |
| Matthew Sykes | Goldman Sachs | Lowers | Buy | $65.00 | $75.00 |
| Vijay Kumar | Evercore ISI Group | Lowers | Outperform | $60.00 | $80.00 |
| Alex Nowark | Craig-Hallum | Lowers | Buy | $65.00 | $82.00 |
| Bruce Jackson | Benchmark | Lowers | Buy | $65.00 | $67.00 |
| Catherine Schulte | Baird | Lowers | Outperform | $67.00 | $70.00 |
| Eve Burstein | Bernstein | Raises | Outperform | $90.00 | $75.00 |
| Kyle Mikson | Canaccord Genuity | Raises | Buy | $95.00 | $75.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Exact Sciences. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Exact Sciences compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Exact Sciences's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Exact Sciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Exact Sciences analyst ratings.
Get to Know Exact Sciences Better
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Exact Sciences: A Financial Overview
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Exact Sciences's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 12.78%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Exact Sciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -5.4% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Exact Sciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.19% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Exact Sciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.57%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Exact Sciences's debt-to-equity ratio is below the industry average. With a ratio of 0.86, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
The Core of Analyst Ratings: What Every Investor Should Know
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
